What are the recommended screening and treatment strategies for psoriasis, taking into account common comorbidities such as cardiovascular disease, metabolic syndrome, depression, anxiety, inflammatory bowel disease, and psoriatic arthritis?

Psoriasis Comorbidities and Treatment

All psoriasis patients require systematic screening for cardiovascular disease, metabolic syndrome, psoriatic arthritis, depression, and inflammatory bowel disease, with screening intensity increased for those with ≥10% body surface area involvement or requiring systemic therapy. 1

Cardiovascular Risk and Metabolic Syndrome Screening

The relationship between psoriasis and cardiovascular disease is severity-dependent, with moderate-to-severe psoriasis showing stronger associations (OR 2.23) compared to mild disease (OR 1.46) 1. This necessitates aggressive cardiovascular risk factor screening:

Screening Protocol

Blood Pressure:

• Every 2 years for all patients; target <120/80 mmHg
• Yearly for age ≥40 or those with BP 130-139/85-89 mmHg, overweight/obese patients, or Black patients 1, 2

Lipid Panel:

• Every 4-6 years for adults aged 20-79 with standard risk factors
• Every 2 years if positive family history, diabetes, or smoking present 2
• Target: Total cholesterol <200 mg/dL, LDL <100 mg/dL, HDL ≥50 mg/dL

Diabetes Screening:

• Every 3 years for adults aged 40-70 with BMI ≥25 kg/m²
• Begin at age 45 for those without risk factors
• Target fasting glucose <100 mg/dL 1, 2

Metabolic Syndrome Assessment (every 2 years):

• Waist circumference: ≥40 inches (men), ≥35 inches (women)
• BMI target <25 kg/m²
• Diagnosis requires ≥3 of: increased waist circumference, BP ≥130/85 mmHg, triglycerides ≥150 mg/dL, low HDL, fasting glucose ≥100 mg/dL 1

Treatment Considerations

Apply a 1.5 multiplication factor to cardiovascular risk calculations for patients with ≥10% body surface area involvement or those requiring systemic/phototherapy 1. This intensified risk stratification acknowledges the independent cardiovascular risk from systemic inflammation. Antihypertensives and statins should be used according to general population guidelines, with treatment performed by either primary care or dermatologist 1.

Psoriatic Arthritis Screening

Screen all psoriasis patients for psoriatic arthritis at every visit using the CASPAR criteria, as early detection and aggressive treatment prevent irreversible joint damage 2.

CASPAR Criteria (≥3 points required with inflammatory arthritis present):

• Current psoriasis: 2 points
• History of psoriasis (if current psoriasis absent): 1 point
• Family history of psoriasis (if no current/past psoriasis): 1 point
• Dactylitis: 1 point
• Juxtaarticular new bone formation: 1 point
• Rheumatoid factor negativity: 1 point
• Nail dystrophy: 1 point

Refer to rheumatology immediately when criteria are met 2. Patients with psoriatic arthritis require additional cardiovascular risk assessment given their elevated risk (risk ratios of 1.3 for hypertension, 1.5 for diabetes, 1.2 for hyperlipidemia) 2.

Depression and Anxiety Screening

Depression affects up to 20% of psoriasis patients and is now understood to result from metabolic inflammation rather than purely psychological stress 3. The inflammatory pattern in psoriatic disease (IL-23, IL-17, TNF, IL-6) directly causes neuroinflammation leading to depression and anxiety 3.

Screen all patients for depression and anxiety at baseline and periodically during follow-up 2, 4. While specific screening intervals aren't defined in guidelines, clinical vigilance is essential, particularly in:

• Patients with obesity (major risk factor for depression)
• Tobacco smokers
• Those with moderate-to-severe disease

Important: Targeted psoriasis treatments (TNF, IL-17, IL-23 inhibitors) can improve depressive symptoms by addressing the underlying neuroinflammation 3. This represents a treatment advantage beyond skin clearance.

Inflammatory Bowel Disease Surveillance

Psoriasis and Crohn's disease share genetic links (IL-23 genotypes) and pathologic connections 2. In case-control studies, 7-11% of Crohn's disease patients had psoriasis versus 1-2% of controls 2.

Maintain high clinical suspicion for IBD symptoms (abdominal pain, diarrhea, rectal bleeding, weight loss) 2. While no specific screening protocols exist, awareness is critical, especially when considering TNF-alpha inhibitors, which treat both conditions but can paradoxically exacerbate multiple sclerosis 2.

Obesity and Lifestyle Management

Obesity shows a severity-dependent relationship with psoriasis (OR 1.66 overall; OR 2.23 for moderate-to-severe disease) 1. Visceral adipose tissue is increased in psoriasis patients and strongly associated with subclinical vascular disease 1.

Lifestyle counseling is mandatory for:

• Adults with type 2 diabetes
• Adults with ≥3 cardiovascular risk factors
• Adults with SBP ≥130 or DBP ≥90 mmHg 1

Weight loss, tobacco cessation, alcohol limitation, and stress reduction improve disease management and reduce comorbidity burden 5.

Additional Screening Considerations

Non-Alcoholic Fatty Liver Disease (NAFLD): Screen with liver function tests and consider ultrasound, particularly in patients with metabolic syndrome 6, 4, 7.

Malignancy Surveillance: Patients treated with PUVA or cyclosporine require close cancer monitoring 2. Follow age-appropriate cancer screening (breast, colon, prostate, skin) per American Cancer Society guidelines 2.

Renal Disease: Consider screening in patients on systemic therapies, particularly cyclosporine 4.

Treatment Selection Based on Comorbidities

When selecting psoriasis treatments, consider comorbidity profiles:

• Metabolic syndrome/cardiovascular disease: Biologics (IL-17, IL-23, TNF inhibitors) may address systemic inflammation
• Depression: TNF, IL-17, IL-23 inhibitors can improve depressive symptoms 3
• Psoriatic arthritis: Biologics and apremilast are preferred
• IBD: TNF inhibitors treat both conditions; avoid in multiple sclerosis 2
• Obesity: Weight loss enhances treatment response; consider agents with favorable metabolic profiles

Common Pitfalls

1. Underestimating cardiovascular risk: Always apply the 1.5 multiplication factor for moderate-to-severe disease 1
2. Missing early psoriatic arthritis: Screen at every visit; joint damage is irreversible 2
3. Attributing depression solely to psychological burden: Recognize it as metabolic inflammation requiring treatment 3
4. Inadequate screening frequency: Intensify monitoring in patients with ≥10% BSA or on systemic therapy 1